CrossAssetDataThe Company File
···
EMBC

Embecta Corp.

Embecta Corp. is classed by the SEC under Surgical & Medical Instruments & Apparatus (industry code 3841), based in Wilmington, DE. In its latest annual figures on file, for the fiscal year ended 2025-09-30, it reported revenue of $1.1 billion and a profit of $95 million (its filed statements).

Product business Surgical & Medical Instruments & Apparatus Wilmington, DE filings since 2021 8 of 9 filed, 1 estimated
Ask the desk about EMBC → Compare EMBC with IRTC → Price chart on TradingView ↗ Full EDGAR file ↗ Watch EMBC →

Sector peers: IRTCINSPGKOSAORT

4.9/10headline grade
vs its business-model standard
5.1/10past 6.1/10present 3.2/10future

Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 3841, Surgical & Medical Instruments & Apparatus); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.

The grade, in three tenses

Headline 4.9 out of ten, 8 of 9 metrics filed and 1 estimated: past 5.1 out of ten, present 6.1 out of ten, future 3.2 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.

The nine metrics

  • Surviving crises (past): 5.5 out of ten. 1 warning event since 2021; the latest 2024-11-29. 55th percentile among 121 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Track record (past): 4.2 out of ten. -0.1% a year over 6 filed years; profitable in 6 of 6. 42nd percentile among 105 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Shareholder treatment (past): 6.2 out of ten. Share count grew 0.8% a year. 35% of cash flow returned. Insiders: 1 sales, 4 purchases. 62nd percentile among 40 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Financial health (present): 5.2 out of ten. Leverage 160%: owes 160¢ per asset dollar. 52nd percentile among 120 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Industry position (present): 6.1 out of ten. top 39% of 109 in its family; net margin 8.8%. 61st percentile among 109 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Leadership (present): 8.0 out of ten. CrossAssetData estimate 8.0/10, confidence 35 of 100 (one part). 80th percentile among 108 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
  • Room to expand (future): 3.9 out of ten. bottom 39% of 104 in its family for room to expand. 39th percentile among 104 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Growth drivers (future): 2.2 out of ten. bottom 22% of 105 in its family for growth drivers. 22nd percentile among 105 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Expectations vs reality (future): 3.2 out of ten. bottom 32% of 88 in its family for expectations against reality. 32nd percentile among 88 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).

The filing record

Newest annual report: Form 10-K filed 2025-11-25 for the period ended 2025-09-30 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-07 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-08-07 (on EDGAR). Newest filing: Form 4, 2026-09-08. Filings on record since 2021. Read from EDGAR 2026-10-12.

Where the revenue comes from

Product and service lines in fiscal 2025: Pen Needles 73%, Safety 13%, Syringes 12%, Manufacturing Facility 2%, Product and Service Other 1%. By geography: United States 54%, Outside the United States 46%. As tagged in its annual report (Form 10-K, filed 2025-11-25).

Who runs it

Kurdikar, Devdatt (President and CEO); Elguicze, Jacob (SVP and CFO); Casner, Jean (Chief Human Resources Officer); Roth, Anthony M. (VP, Chief Accounting Officer); Mann, Jeffrey Z (Pres, Pharm Svc&Prod Mgmt, CLO); Curtis, Shaun (SVP, Global Manuf./Sup. Chain); Morris, Milton Mayo (director); Hombach, Robert J. (director); Anderson, Carrie L (director); Pomeroy, Claire (director); and 2 more. 12 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.

This file: Overview · Past · Present · Future · Filings · every company on file

Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.